Immuneering Corporation

IMRX
$5.28 (+ $0.19 + 3.63%)
Last updated: 2026-07-08 15:40 UTC
IMRX Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS45254E1073
CUSIP45254E107
Market Price5.29
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.79
Market Cap$439.7M
Book Value3.59
Price to Book1.896
Beta0.46
52w High10.08
52w Low1.1
Next Earnings DateN/A

Immuneering Corporation trades under ticker IMRX on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US45254E1073, CUSIP 45254E107.

About the Company
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Price History